Takeda Pharmaceutical Company Limited (4502.T)
| Previous close | 4,138.00 |
| Open | 4,150.00 |
| Bid | 4,126.00 x 0 |
| Ask | 4,131.00 x 0 |
| Day's range | 4,105.00 - 4,158.00 |
| 52-week range | 3,900.00 - 4,873.00 |
| Volume | |
| Avg. volume | 4,273,261 |
| Market cap | 6.493T |
| Beta (5Y monthly) | 0.54 |
| PE ratio (TTM) | 45.45 |
| EPS (TTM) | 90.86 |
| Earnings date | 31 Jul 2024 |
| Forward dividend & yield | 196.00 (4.74%) |
| Ex-dividend date | 27 Sept 2024 |
| 1y target est | 4,814.00 |
Business WireTakeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting
OSAKA, Japan & CAMBRIDGE, Mass., May 14, 2024--Takeda (TSE: 4502/NYSE:TAK) today announced that it will present data from its oncology pipeline and product portfolio at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held May 31-June 4, 2024, in Chicago, Ill.
Business WireAC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
OSAKA, Japan & CAMBRIDGE, Mass & LAUSANNE, Switzerland, May 13, 2024--Takeda (TSE:4502/NYSE:TAK) and AC Immune SA (NASDAQ: ACIU) today announced an exclusive, worldwide option and license agreement for AC Immune’s active immunotherapies targeting toxic forms of amyloid beta (Abeta), including ACI-24.060 for the treatment of Alzheimer’s disease.
Investor's Business DailyCatalyst's New CEO Has Big Ideas For The Small Biotech
Richard Daly has watched Catalyst Pharmaceuticals transform. Now, as the company's new CEO, he has some metamorphic ideas of his own.
